Condition: Retinitis Pigmentosa · Sponsor: Kiora Pharmaceuticals, Inc.
The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in patients with late-stage retinitis pigmentosa (RP). Late-stage RP patients will include those patients with No Light Perception (NLP), or Low Vision (LV).
This description comes directly from the study's public registry record.
Claudia Gregorio-King · +61 421 992 076 · clinical@kiorapharma.com
Always discuss trial participation with your own doctor first.
| Save Sight Institute | Sydney, New South Wales, Australia | Recruiting |
| Queensland Eye Institute | Woolloongabba, Queensland, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Cerulea Clinical Trials | East Melbourne, Victoria, Australia | Recruiting |
| Lions Eye Institute | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06628947